PerkinElmer to Divest Proteomics Business to Concentrate on Human, Environmental Health

It was not immediately clear whether PerkinElmer would divest all of its proteomics assets or retain a portion of them, though it described them as “discontinued operations” during its fourth-quarter earnings statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories